CARD10 Antibody

What is CARD10 and why is it significant in immunological research?

CARD10, also known as CARMA3 or BIMP1, belongs to the membrane-associated guanylate kinase-like (MAGUK) family of proteins that function as molecular scaffolds in signal transduction pathways. CARD10 is particularly significant in immunological research because it activates the NF-κB pathway following G-protein-coupled receptor- and epidermal growth factor receptor-induced signaling .

CARD10's importance is highlighted by its role in both immune signaling and disease pathogenesis:

• It forms a complex with BCL10 and MALT1, which is critical for multiple signaling pathways including NF-κB, c-Jun N-terminal kinase, and mammalian target of rapamycin

• Mutations in CARD10 have been associated with primary immunodeficiency and autoimmune conditions

• Recent research suggests CARD10's involvement in inflammatory bowel diseases, particularly Crohn's disease

What applications are CARD10 antibodies typically used for?

CARD10 antibodies can be utilized for multiple research applications:

Most CARD10 antibodies show reactivity against human samples, with some products also cross-reacting with mouse and rat tissues . Positive controls frequently include human kidney tissue or colon cancer tissue .

How should CARD10 antibodies be stored and handled for optimal results?

For maximum stability and activity, CARD10 antibodies should be:

• Stored at -20°C prior to opening

• Aliquoted to avoid repeated freeze-thaw cycles, which can degrade antibody performance

• Upon initial thawing, centrifuged if not completely clear

• Stable for several weeks at 4°C as an undiluted liquid

• Diluted only immediately before use

Most commercial CARD10 antibodies are formulated in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . This formulation helps maintain stability during storage.

What are the common challenges in CARD10 immunodetection and how can they be addressed?

Several challenges may arise when using CARD10 antibodies:

Challenge 1: Background signal in IHC

• Solution: Optimize antigen retrieval methods. Data suggests using TE buffer at pH 9.0, though citrate buffer at pH 6.0 may be an alternative

• Implement proper blocking steps to reduce non-specific binding

• Titrate antibody concentration carefully (typically starting at 1:50-1:500 for IHC)

Challenge 2: Specificity confirmation

• Solution: Use appropriate positive controls such as human kidney or colon cancer tissue

• Consider using blocking peptides when available (e.g., PEP-1407 with PA5-34364)

• Compare results from multiple CARD10 antibodies targeting different epitopes

Challenge 3: Sample preparation

• Solution: Ensure proper fixation and processing of tissues

• For cell lines, verify CARD10 expression levels in your specific cell type before experimentation

How can CARD10 antibodies be employed to study CARD10 mutations associated with immunodeficiency?

Research indicates that CARD10 mutations can lead to a novel form of autosomal recessive genetic disease characterized by primary immunodeficiency with autoimmune manifestations . When investigating such mutations:

• Mutation detection strategy: Use genomic DNA sequencing to identify mutations, then confirm protein expression changes using CARD10 antibodies in Western blot analysis to detect altered molecular weight or expression levels

• Functional analysis workflow:

  • Perform reconstitution studies to assess CARD10 mRNA and protein expression in patient samples compared to controls

  • Use CARD10 antibodies in co-immunoprecipitation assays to evaluate interactions with binding partners like BCL10

  • Analyze NF-κB pathway activation through reporter assays and phospho-specific antibodies

• Phenotypic correlation:

  • Apply CARD10 antibodies in immunohistochemistry of affected tissues (e.g., gastrointestinal biopsies)

  • Correlate findings with clinical manifestations such as Crohn's disease, allergic responses, and recurrent infections

In a reported case study, a homozygous R420C mutation in CARD10's coiled-coil domain was identified in siblings with immunodeficiency. Western blot analysis with CARD10 antibodies revealed decreased protein expression, correlating with clinical symptoms including recurrent infections, gastrointestinal disorders, and allergic manifestations .

What considerations are important when designing experiments to study CARD10-mediated NF-κB activation?

CARD10 plays a critical role in NF-κB activation through interaction with BCL10. When designing experiments to study this process:

• Stimulus selection: Choose appropriate stimuli known to activate CARD10-mediated pathways:

  • G-protein coupled receptor agonists

  • Epidermal growth factor receptor ligands

• Experimental readouts:

  • Direct NF-κB activation markers: p65 nuclear translocation, IκBα degradation

  • Downstream gene expression: IL-8, GROα, MCP-1, other NF-κB target genes

  • Chemokine production: Analyze using multiplex assays, as CARD10 mutations are associated with altered chemokine profiles

• Cell type considerations:

  • Select cell types with high CARD10 expression (epithelial cells, monocytes)

  • Consider using monocyte subsets (classical CD14highCD16−, intermediate CD14highCD16+, nonclassical CD14+CD16high) as CARD10 functions differently across these populations

• Controls for specificity:

  • CARD10 knockdown/knockout controls

  • Compare effects of mutations in different CARD domains (CARD, coiled-coil, PDZ)

  • Use mutants that disrupt specific protein interactions

Research has shown that CARD10-deficient cells exhibit impaired dendritic cell maturation and antigen presentation, highlighting the importance of including these parameters in experimental designs .

How can epitope mapping be performed to evaluate CARD10 antibody specificity and functionality?

Epitope mapping is crucial for characterizing CARD10 antibodies and understanding their utility in different applications:

• Recombinant protein fragment approach:

  • Generate overlapping recombinant CARD10 fragments covering different domains (CARD domain, coiled-coil domain, PDZ domain, SH3 domain, GUK domain)

  • Express these fragments with appropriate tags for purification

  • Perform Western blot analysis with the CARD10 antibody to identify reactive fragments

• Peptide array methods:

  • Synthesize overlapping peptides (typically 15-20 amino acids with 5-10 amino acid overlaps) spanning the entire CARD10 sequence

  • Spot peptides onto membranes and probe with the CARD10 antibody

  • Identify reactive peptides to narrow down the epitope

• Validation using mutant proteins:

  • Generate site-specific mutations in key residues within the identified epitope

  • Test antibody reactivity against these mutants

  • Compare results with structural data if available

Several commercial CARD10 antibodies target different epitopes:

• Some target the CARD domain (amino acids 1-116)

• Others target the C-terminal region (amino acids 863-1032)

• Some antibodies are raised against synthetic peptides corresponding to 14 amino acids at the C-terminus

Understanding the exact epitope is particularly important when studying CARD10 mutations, as antibodies targeting the mutation site may show altered binding patterns.

What methodological approaches can be used to investigate CARD10's role in immune cell subset functions?

CARD10 has differential effects across immune cell populations. To investigate its role:

• Cell isolation and characterization protocol:

  • Isolate specific monocyte subsets (CD14highCD16−, CD14highCD16+, CD14+CD16high) using magnetic bead separation or FACS

  • Verify monocyte-derived HLADR+CD11c+CD16+ populations

  • Confirm CARD10 expression in each population via Western blot

• Functional assessment workflow:

  • Measure chemokine production (IL-8, GROα, MCP-1, MIP-1α, SDF1α)

  • Assess cytokine responses (IL-6, TNFα, IFNα, IL-1α)

  • Evaluate NF-κB pathway activation

  • Analyze cell maturation markers

• Comparison between genotypes:

  • Wild-type vs. CARD10 mutant cells

  • Heterozygous vs. homozygous mutation carriers

  • Consider environmental factors that may influence phenotype expression

Research has shown that in a family with CARD10 mutations, the numbers of CD14highCD16+, CD14+CD16high, and monocyte-derived HLADR+CD11c+CD16+ cells were reduced compared to unaffected family members . Additionally, cytokine assays revealed elevated levels of specific chemokines (IL-8, GROα, MCP-1) but normal or decreased levels of other inflammatory factors (IL-6, TNFα, IFNα) .

How can researchers validate and troubleshoot CARD10 antibodies in multiparameter flow cytometry?

Flow cytometry applications with CARD10 antibodies require careful validation:

• Initial validation protocol:

  • Perform titration experiments to determine optimal antibody concentration

  • Compare staining patterns in positive control cells (expressing CARD10) vs. negative controls

  • Use complementary techniques (Western blot, IF) to confirm specificity

• Multiparameter panel design considerations:

  • Select fluorophores with minimal spectral overlap with other markers

  • Consider CARD10's predominantly cytoplasmic localization when designing permeabilization protocols

  • Include lineage markers to identify specific cell populations of interest

• Troubleshooting approach for weak or nonspecific signals:

  • Optimize fixation and permeabilization conditions (try different commercial kits)

  • Test alternative clone if available (polyclonal vs. monoclonal)

  • Consider signal amplification methods

  • Check for potential interfering factors in buffers

For CARD10 analysis in monocyte subsets, research indicates the importance of carefully gating strategies to distinguish CD14highCD16−, CD14highCD16+, and CD14+CD16high populations, as these show differential CARD10 function and expression .

What are the methodological considerations when investigating CARD10's role in epithelial tissue and inflammatory bowel disease?

Given CARD10's high expression in epithelial cells of the gastrointestinal tract and its potential link to inflammatory bowel disease:

• Tissue processing and staining protocol:

  • Optimize fixation conditions for epithelial tissues

  • Test multiple antigen retrieval methods (TE buffer pH 9.0 is recommended )

  • Use appropriate positive controls (human colon cancer tissue )

• Comparative analysis methodology:

  • Compare CARD10 expression between Crohn's disease, ulcerative colitis, and healthy controls

  • Assess cellular localization and expression levels

  • Correlate with disease activity indices

• Functional studies in epithelial models:

  • Use intestinal epithelial cell lines (Caco-2, HT-29) for in vitro studies

  • Investigate CARD10's role in TLR4 signaling and epithelial barrier function

  • Examine effects on NF-κB activation in response to bacterial components

Research has shown significantly lower CARD10 gene expression in Crohn's disease patients compared to ulcerative colitis patients and healthy controls . Additionally, the CARD10-BCL10-MALT1 complex has been implicated in TLR4 signaling, suggesting its importance in intestinal immunity and barrier function .